Key Takeaways
- A DSO practice multiple applies to normalized EBITDA, not collections, to estimate enterprise value in a DSO affiliation.
- Normalized EBITDA starts with reported net income, then adds back above-market owner pay, personal expenses, one-time costs, and rent adjustments.
- In 2026, DSO multiples generally range from 4x–8x for smaller practices and up to 11x+ for platform-grade groups with $5M+ in normalized EBITDA.
- Enterprise value comes from multiplying normalized EBITDA by the selected DSO multiple; in the example, $714K EBITDA supports a $3.57M–$4.99M range.
- McLerran & Associates provides diligence-grade valuations and side-by-side buyer comparisons; schedule a free, confidential discovery call to understand your practice’s likely market value before speaking with any buyer.
Why Normalized EBITDA Drives DSO Valuations
Normalized EBITDA is the starting point for any DSO practice multiple. Buyers want to see what the practice would earn under institutional ownership, not under a specific owner’s lifestyle and tax planning choices.
Normalized EBITDA removes above-market owner compensation, personal expenses, and one-time costs, then adjusts related-party rent to fair-market levels. The result is a consistent earnings figure that DSOs can compare across many practices.
The distinction between buyer types shapes how this figure is used. A private buyer, usually another dentist using SBA financing, often values a practice at roughly 65–85% of annual collections. That approach reflects lending limits more than a detailed profitability analysis and can produce a very different price than a DSO valuation based on EBITDA.
The information gap between owners and DSOs can be significant. A DSO negotiates acquisitions every week, while most dentists sell only once. Without a diligence-grade EBITDA analysis prepared in advance, the buyer’s number tends to become the anchor, and that anchor can quietly determine the seller’s final outcome.
How to Calculate Normalized EBITDA
The normalization process follows five sequential steps. Each adjustment needs clear documentation, because aggressive or poorly supported add-backs can reduce credibility across the entire schedule.
- Start with reported net income. Pull 3 years of tax returns, profit-and-loss statements, and current year-to-date financials. Add back interest, taxes, depreciation, and amortization to arrive at reported EBITDA, which serves as the standard accounting baseline.
- Normalize owner-doctor compensation. Replace the owner’s actual W-2 and distributions with a fair-market replacement cost. For many general practitioners, that figure can be 28–32% of the owner’s personally produced collections, which often creates $80K–$300K of EBITDA uplift in solo-producer practices. This adjustment is usually the largest single change in the schedule.
- Add back personal expenses run through the practice. Common personal expenses include vehicle costs, family-member compensation above market rates, personal cell phone and club memberships, and the personal portion of travel labeled as continuing education. For established practices, these adjustments often total $25K–$75K each year.
- Remove one-time and non-recurring items. One-time equipment purchases that were fully expensed in a single year, non-recurring legal fees, and similar items can be added back when they clearly will not recur under normal operations. Only items with documentation showing that they are truly non-recurring qualify as reliable add-backs.
- Adjust related-party rent. When the practice owner also owns the building, rent on the profit-and-loss statement is reset to a third-party fair-market level, often 5–8% of collections. Below-market rent reduces normalized EBITDA, while above-market rent increases it.
Healthy dental practices often achieve normalized EBITDA margins of 18–28% of collections, with high-performing practices reaching 30% or more. Margins below roughly 15% can reduce buyer interest and compress multiples.
Building Your Normalization Schedule in a Spreadsheet
A structured spreadsheet template can walk through these five steps in a consistent way. The template pulls reported figures into a normalization schedule, applies each adjustment category as a labeled line item, and produces a single normalized EBITDA figure with a supporting schedule that a buyer’s quality-of-earnings team can follow.
Creating a schedule that holds up under buyer review usually requires more than a template. The work often includes cross-referencing practice management software data against tax returns and supporting each adjustment with clear documentation. McLerran & Associates completes this diligence-grade analysis before a practice goes to market so the EBITDA figure remains credible when buyers review it.
Schedule a free, confidential discovery call with McLerran & Associates to have a CPA-led team build and defend your normalization schedule before any buyer sees your financials.
2026 DSO Practice Multiple Ranges by EBITDA Tier
In 2026, DSO multiples tend to increase as normalized EBITDA grows. Larger EBITDA often signals greater scale, stronger systems, and more buyer competition.
The table below summarizes indicative ranges based on current market data.
| Practice Tier | Normalized EBITDA Range | Indicative 2026 DSO Multiple Range | Typical Buyer Profile |
|---|---|---|---|
| Single-doctor add-on | Under $1M | 4x–8x | Small to mid-size DSO tuck-in |
| Multi-doctor regional add-on | $1M–$3M | 8x–11x | Regional DSO add-on buyer |
| Emerging multi-location platform | $3M–$5M | 9x–11x | Strategic or platform acquirer |
| Platform-grade group | $5M+ | 11x and above (select cases) | PE-backed platform buyer |
Headline EBITDA multiples have stayed relatively stable in recent years. At the same time, the spread between the strongest and middle-of-the-pack offers on the same practice has widened in 2026. Specialty practices can sometimes command higher ranges than general dentistry at similar EBITDA levels, although those premiums vary by specialty, buyer, and local market conditions.
Worked Example: Normalizing a $2M Revenue Practice
Consider a single-location general dental practice with $2M in annual collections and reported net income of $300K. A simplified normalization schedule could look like this:
- Reported net income: $300,000
- Add back: interest, taxes, depreciation, amortization: +$60,000
- Reported EBITDA: $360,000
- Add back: owner compensation above market rate (owner W-2 of $480K vs. $160K market replacement cost): +$320,000
- Add back: personal vehicle, club memberships, personal travel: +$40,000
- Add back: one-time legal fees from a prior dispute: +$18,000
- Rent adjustment (owner-occupied building, rent below market by $24K per year): –$24,000
- Normalized EBITDA: $714,000
This normalized EBITDA margin of about 35.7% of collections falls within the healthy normalized range for general practices after owner compensation adjustments. With that normalized EBITDA figure in hand, the next step is converting it into an estimated enterprise value.
Translating Normalized EBITDA into Enterprise Value
Enterprise value, meaning the total price a buyer pays for the business, comes from applying a multiple to normalized EBITDA.
Enterprise Value = Normalized EBITDA × DSO Practice Multiple
Using the $714,000 normalized EBITDA from the example and a single-doctor add-on range of 5x–7x:
- Low end: $714,000 × 5 = $3,570,000
- High end: $714,000 × 7 = $4,998,000
The gap between the low and high ends of that range, nearly $1.4M, shows how much impact buyer competition and deal structure can have on a seller’s outcome.
Practice Traits That Influence Your Multiple
Several practice-specific traits can move a multiple toward the top or bottom of its range. Some factors tend to reduce perceived risk, while others increase it.
Owner dependence is often the most influential factor. Practices where the owner-doctor produces more than 90% of clinical revenue can face a valuation reduction, because buyers hesitate to pay for production that may leave with the seller.
On the positive side, strong hygiene revenue can support higher multiples. Hygiene revenue above 30% of collections often signals a stable, transferable patient base, which many DSOs value highly.
Payer mix can work in either direction. Medicaid exposure above 40% of revenue can trigger a multiple discount, because many DSOs underwrite payer mix conservatively.
Growth history also matters. A practice with 3 years of consistent revenue and earnings growth often commands a higher multiple than a flat practice, even when current EBITDA is similar.
Lease terms influence value as well. Leases that expire within 24 months or include above-market rent can compress multiples. In contrast, leases with at least 5 years remaining and rent below about 8% of revenue tend to support stronger pricing.
Technology and facility condition play a role. Modern practice management systems and digital imaging technology can support premium multiples, while deferred capital upgrades often reduce value as buyers factor in post-close investment.
Management depth can further enhance multiples. A trained non-owner team, documented standard operating procedures, and clear KPI dashboards can add meaningfully to EBITDA multiples by reducing reliance on the selling doctor’s personal goodwill.
Comparing Private-Buyer and DSO Outcomes
Using the same $714,000 normalized EBITDA from the example, private-buyer and DSO pathways can produce very different headline values and payment structures.
A private buyer, usually another dentist using conventional or SBA financing, would likely value the $2M revenue practice at 65–85% of collections, which produces a range of $1.3M–$1.7M. That amount usually arrives as 80–100% cash at close, with a short 4–8 week transition and no long-term employment requirement.
A DSO buyer applying a 5x–7x multiple to the $714,000 normalized EBITDA produces a headline range of $3.57M–$4.99M. However, DSO offers in 2026 often include 60–80% of total consideration as cash at close, with the balance in rollover equity and possibly an earnout tied to post-close performance.
That rollover equity, which can represent up to 40% of total deal value, usually remains illiquid until the DSO itself sells, often 5–7 years later. The selling doctor typically signs a 3–5 year employment agreement as part of the transaction.
Neither pathway fits every owner. The better choice depends on financial goals, timing, risk tolerance, and preferences for patients and staff after the transition. Because McLerran & Associates regularly works both pathways, the firm can build a side-by-side comparison that focuses on after-tax proceeds over time rather than headline prices alone.
Common Normalization Challenges in Dental Sales
Several recurring issues tend to surface when normalizing EBITDA for dental practice transactions.
Contested owner compensation add-backs. This adjustment is frequently the most debated. Owner compensation normalization often represents the largest EBITDA change in DSO sales, and quality-of-earnings teams usually review it closely. A strong defense relies on documented production data, market-rate benchmarks, and a consistent methodology.
Soft add-backs that do not survive diligence. Soft add-backs, such as related-party expenses, above-market rent, and discretionary spending, are commonly challenged. Listing them without clear support can weaken confidence in the entire normalization schedule.
Data gaps and inconsistent reporting. In one example, a multi-location practice with over $12M in annual collections produced EBITDA estimates ranging from $1.5M to $2.6M when 18 institutional bidders applied their own normalization methods to the same data. Controlling the EBITDA narrative before going to market can help prevent buyers from anchoring on the lowest defensible figure.
McLerran & Associates prepares the normalization analysis before any buyer review, then supports it through diligence while reminding buyers that a vetted pool of competing bidders is available if they attempt to re-trade value.
Frequently Asked Questions
What is the difference between a DSO practice multiple and Days Sales Outstanding?
These terms share an acronym but describe different concepts. Days Sales Outstanding is an accounting metric that measures how many days it takes a business to collect payment after a sale. It does not play a role in dental practice merger-and-acquisition valuation.
A DSO practice multiple, in this context, refers to the EBITDA multiple that a Dental Service Organization applies when pricing a practice acquisition. Because search results often mix these definitions, confirming the intended meaning before relying on any valuation guidance can be helpful.
How many years of financials are needed to calculate normalized EBITDA?
Most institutional buyers and sell-side advisors use 3 years of tax returns and profit-and-loss statements, plus current year-to-date financials, to build a normalized EBITDA schedule. Three years of data helps distinguish truly one-time items from recurring expenses and highlights revenue trends that buyers will underwrite.
A single year of financials rarely supports a defensible normalization, especially if that year was unusually strong or weak compared with prior periods.
Can a practice with high owner production still attract DSO interest?
High owner production can still attract DSO interest, but it often introduces valuation risk. Practices where the selling dentist produces a large share of clinical revenue create transition risk that buyers may reflect through a lower multiple, a larger earnout, or a longer required employment period after closing.
Reducing owner production as a share of total practice production before going to market can be one of the more effective ways to improve a multiple. McLerran & Associates evaluates this dynamic in each engagement and can discuss whether operational changes before a sale are likely to be worthwhile.
Is the DSO multiple applied to collections or to EBITDA?
DSO buyers apply the multiple to normalized EBITDA, not to collections. Private buyers, usually individual dentists using bank financing, often value practices as a percentage of annual collections because that method aligns with how lenders underwrite SBA loans.
These two methods can produce very different headline numbers for the same practice. Comparing a DSO offer to a private-buyer offer usually works best when both are translated into a common metric, such as after-tax cash proceeds over a defined time period.
When is the right time to get a practice valuation?
Many owners find value in a formal valuation earlier than they expect. A diligence-grade valuation can be useful 2–5 years before a sale, when there is still time to address factors that may suppress value, such as owner dependence, payer mix, lease terms, or technology gaps.
McLerran & Associates will update a valuation for free 1 year after the initial engagement if the owner is not yet ready to transact, which can make an early valuation a relatively low-risk starting point.
Schedule a free, confidential discovery call with McLerran & Associates. With roughly 2,000 completed practice sales and more than 10,000 practices evaluated, the firm’s sell-side team can outline what your practice may be worth in both markets and what, if anything, to address before going to market.
